2 patents currently held
14 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
5 more records may belong here and await a decision; they are not counted.
The next term ends in Aug 2027. from the record
Of the 14 now held by other companies, 8 name Immunoforge Co. Ltd. as their current owner, and 6 more name another party. Each row says which.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
1
Ending by 2030
Aug 2027
Next term end
2
Patent families
When these terms end
Held patents by the year their term ends
notable patents
all others
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Only 2 of the currently held patents qualify as notable.
Notable
Ends Aug 2027 · High confidence
Also notable
Ends Aug 2042 · High confidence
Multimeric Elp Fusion Constructs
US 7,709,227
Renewed at every maintenance window since the 2010 grant; no more fees are due before its term ends in 2027.
Methods of Reversing Ticagrelor Activity
US 12,617,870
Granted 2026. Too new for citation comparison; protection runs to 2042.
Formerly held, still cited
Notable
Ends Dec 2037 · High confidence
Cited by 8 later US patents, top 25% of utility patents granted in 2020 in our data. Protection runs to 2037.
now held by Corxel Pharmaceuticals, Inc.
Also notable
Ends Feb 2036 · High confidence
The newest of the three, granted 2020. It anchors the portfolio to 2036, later than anything else here.
now held by Immunoforge Co., Ltd.
Also notable
Ends Aug 2030 · High confidence
Granted 2017 and renewed at every maintenance window due so far. Protection runs to 2030. A terminal disclaimer caps this term to an earlier patent's.
now held by Immunoforge Co., Ltd.
Fee deadlines
No maintenance fee falls due on this company's record before Nov 10, 2027.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
What they patent
Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
| Methods of Reversing Ticagrelor Activity | 1 in force | to Aug 2042 |
| Multimeric Elp Fusion Constructs | 1 in force | to Aug 2027 |
Patents held now
Soonest term end first.
Showing 1 to 2 of 2
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,709,227 | Multimeric Elp Fusion Constructs In force · High confidence | In force | High confidence | |
| US 12,617,870 | Methods of Reversing Ticagrelor Activity In force · High confidence | In force | High confidence |
Also on record, not counted in the 2: 14 patents in force now held by others · 23 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.